Long‑serving LSS readers will know the admiration we’ve expressed for CAR‑T therapy (Chimeric Antigen Receptor T‑cells) and the extraordinary advances it has brought to cancer treatment. So it was a genuine surprise this morning when our researchers stumbled upon a credible alternative approach — spotted first via the excellent science feed of Hashem Al‑Ghaili.
The substance in question is GTB‑5550, a tri‑specific natural‑killer‑cell engager developed by GT Biopharma. According to Al‑Ghaili’s summary, GTB‑5550 anchors to a specific protein on the cancer cell, binds to an activating receptor on the patient’s natural‑killer (NK) cells to form an immunological bridge, and delivers an immune‑signalling protein that drives those NK cells to multiply and sustain their attack.
The underlying science is real and verifiable: GT Biopharma has FDA clearance for Phase 1 trials, and the National Cancer Institute lists an active study in advanced solid tumours. Readers can consult the company’s announcement at [3].
What caught our eye, however, was Al‑Ghaili’s shrewd observation that this line of attack offers a potential alternative — or at least a practicable complement — to the often intricate and labour‑intensive CAR‑T process. LSS has always championed redundant capacity over just‑in‑time efficiency: think bacteriophages alongside antibiotics, quantum computing alongside AI, and now, perhaps, NK‑cell engagers alongside CAR‑T.
We just didn’t expect CAR‑T to acquire a rival quite so soon.
[2] https://www.facebook.com/ScienceNaturePage/posts/pfbid0YtDt88h5ryQi482butNALJQQ2parbD1YsQsFRUdZp
[3] GT Biopharma, Inc. (2026). GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma. GlobeNewswire.
# Hashem Al‑Ghaili #CAR-T #GTB 5550 #cancer #immunology #medicine #health #GT Biopharma #FDA
